论文部分内容阅读
目的观察吸入沙美特罗联合丙酸氟替卡松对重度慢性阻塞性肺疾病(COPD)患者肺功能的影响。方法随机将80例患者分为沙美特罗组(对照组)和沙美特罗联合丙酸氟替卡松组(试验组)各40例,所有患者均给予常规吸氧、抗感染、化痰、平喘、对症治疗。对照组应用沙美特罗,试验组应用沙美特罗联合丙酸氟替卡松,出院后对照组继续使用沙美特罗,试验组继续使用沙美特罗联合丙酸氟替卡松,随访观察6个月。两组均于治疗前及出院6个月检查肺功能,进行血气分析。结果治疗前两组的第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC、FEV1占预计值百分比(FEV1%)、动脉血氧分压(PaO2)、动脉血二氧化碳分压(PCO2)]的差异均无统计意义(P>0.05);治疗后试验组较对照组症状有明显改善(P<0.05)。结论沙美特罗联合丙酸氟替卡松对重度COPD患者肺功能有显著的改善作用。
Objective To observe the effects of inhaled salmeterol and fluticasone propionate on pulmonary function in patients with severe chronic obstructive pulmonary disease (COPD). Methods Eighty patients were randomly divided into salmeterol group (control group) and salmeterol combined with fluticasone propionate group (experimental group) of 40 cases, all patients were given conventional oxygen, anti-infection, phlegm, Symptomatic treatment. In the control group, salmeterol was used in the control group. Salmeterol combined with fluticasone propionate was used in the control group. Salmeterol was continued in the control group after discharge from the control group. Salmeterol combined with fluticasone propionate in the control group was followed up for 6 months. Both groups were examined before and 6 months after discharge pulmonary function, blood gas analysis. Results The FEV1, FVC, FEV1 / FVC, FEV1 percentage of predicted value (FEV1%), PaO2, arterial blood carbon dioxide (P> 0.05). After treatment, the symptoms of the experimental group were significantly improved compared with the control group (P <0.05). Conclusion Salmeterol combined with fluticasone propionate can significantly improve pulmonary function in patients with severe COPD.